Evolution of AZT resistance in HIV-1: The 41-70 intermediate that is not observed in Vivo has a replication defect

Virology

Volumn 283, Issue 2, 2001, Pages 294-305

  Jeeninga, Rienk E ^a   Keulen, Wilco ^b   Boucher, Charles ^b   Sanders, Rogier W ^a   Berkhout, Ben ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

AMINO ACID ANALYSIS; AMINO ACID SUBSTITUTION; ARTICLE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UTERINE CERVIX CARCINOMA; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0035837049     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2001.0888     Document Type: Article

References (64)

1. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine
2. The processivity of DNA synthesis exhibited by drug-resistant variants of human immunodeficiency virus type-1 reverse transcriptase
3. Limiting dNTP concentrations emphasize the processivity defect of lamivudine-resistant variants of HIV-1 reverse transcriptase
4. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme
5. HIV-1 evolution under pressure of protease inhibitors, climbing the stairs of viral fitness
6. Resistance of HIV-1 to protease inhibitors: Selection of resistance mutations in the presence and in the absence of the drug
7. Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay
8. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects
9. Effects of discontinuation of zidovudine treatment on the zidovudine sensitivity of HIV-1 isolates
10. Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1
11. Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication
12. Effects of human immunodeficiency virus type 1 resistance to protease inhibitors on reverse transcriptase processing, activity, and drug sensitivity
13. Evolution of zidovudine resistance-associated genotypes in human immunodeficiency virus type 1-infected patients
14. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy
15. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors
16. A hairpin structure in the R region of the human immunodeficiency virus type 1 RNA genome is instrumental in polyadenylation site selection
17. A conserved hairpin motif in the R-U5 region of the human immunodeficiency virus type 1 RNA genome is essential for replication
18. Improved envelop function selected by long-term cultivation of a translation-impaired HIV-1 mutant
19. Novel Gag-Pol frameshift site in human immunodeficiency virus type 1 variants resistant to protease inhibitors
20. Immunological and pharmacological approaches to the control of retroviral infections
21. The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection
22. The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cic-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
23. Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215
24. Mutational analysis of Phe 160 within the "palm" subdomain of Human Immunodeficiency virus type 1 reverse transcriptase
25. Relative replication fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro
26. An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to AZT
27. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: Implications for drug resistance
28. Functional differences between the LTR transcriptional promoters of HIV-1 subtypes A through G
29. Resistance of HIV-1 reverse transcriptase against TSAO derivatives is determined by the mutation Glu138Lys on the p51 subunit
30. Fifth mutation in HIV-1 reverse transcriptase contributes to the development of high level resistance to zidovudine
31. Initial appearance of the 184lle variant in lamivudine-treated patients is caused by the mutational bias of the human immunodeficiency virus type 1 reverse transcriptase
32. Nucleotide substitution patterns can predict the requirements for drug-resistance of HIV-1 proteins
33. Increased polymerase fidelity of lamivudine-resistant HIV-1 variants does not limit their evolutionary potential
34. Evolution of a disrupted TAR RNA hairpin structure in the HIV-1 virus
35. Natural variants of the HIV-1 long terminal repeat: Analysis of promoters with duplicated DNA regulatory motifs
36. Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an in vitro competitive HIV-1 replication assay
37. MOLSCRIPT: A program to produce both detailed and schematic plots of protein structures
38. Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase
39. Zidovudine resistant human immunodeficiency virus selected by passage in cell culture
40. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy
41. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)
42. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine
43. A colorimetric reverse transcriptase (RT) assay optimized for Moloney murine leukemia virus, and its use for characterization of RTs of unknown identity
44. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: Phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients
45. Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: Effects on infectivity and neutralization
46. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective
47. Raster3D Photorealistic molecular graphics
48. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
49. Human retroviruses and AIDS
50. Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy
51. Kinetics of human immunodeficiency virus type 1 reverse transcription in blood mononuclear phagocytes are slowed by limitations of nucleotide precursors
52. Second-site reversion of a human immunodeficiency virus type 1 reverse transcriptase mutant that restores enzyme function and replication capacity
53. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection
54. Altering the intracellular environment increases the frequency of tandem repeat deletion during Moloney murine leukemia virus reverse transcription
55. Pure nucleoside enantiomers of β-2′,3′-dideoxycytidine analogs are selective inhibitors of hepatitis B virus in vitro
56. Monoclonal antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell lines
57. Reversion of a human immunodeficiency virus type 1 integrase mutant at a second site restores enzyme function and virus infectivity
58. A second-site mutation that restores replication of a Tat-defective human immunodeficiency virus
59. Mutation patterns of the reverse transcriptase and protease genes in human immunodeficiency virus type 1-infected patients undergoing combination therapy: Survey of 787 sequences
60. A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection
61. Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconverters infected with zidovudine-resistant variants
62. Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle
63. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo